Company: VERA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-314244
Chunk: 49

Company: Vera Therapeutics, Inc.
Filing Date: 2025-12-10
Form: 424B5
Chunk 49
---
; |

| • |     | conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments              
 in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; |

| • |     | ranking, if applicable; |

| • |     | restrictive covenants, if any; |

| • |     | voting or other rights, if any; and |

| • |     | important U.S. federal income tax considerations. |

The applicable prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part. This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement. We or selling securityholders may sell the securities directly to investors or through underwriters, dealers or agents. We, and our underwriters or agents, reserve the right to accept or reject all or part of any proposed

4

purchase of securities. If we or selling securityholders do offer securities through underwriters or agents, we will include in the applicable prospectus supplement:

| • |     | the names of those underwriters or agents; |

| • |     | applicable fees, discounts and commissions to be paid to them; |

| • |     | details regarding options to purchase additional securities, if any; and |

| • |     | the estimated net proceeds to us. |

Class A Common Stock. We or selling securityholders may sell shares of our Class A common stock from time to time. Holders of our Class A common stock are entitled to one vote per share for the election of directors and on all other matters that require stockholder approval. Subject to any preferential rights of any then outstanding preferred stock, in the event of our liquidation, dissolution or winding up, holders of our Class A common stock are entitled to share ratably with holders of our Class B common stock in the assets remaining after payment of liabilities and the liquidation preferences of any then outstanding preferred stock. Our Class A common stock does not carry any preemptive rights enabling a holder to subscribe for, or receive shares of, our Class A common stock or any